Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by BNP Paribas Financial Markets

Key Points

• BNP Paribas Financial Markets reduced its Teva position by 10.3% in the fourth quarter, selling 64,277 shares and ending with 561,231 shares valued at about $17.5 million.
• Several analysts turned more bullish on Teva, with firms including Bank of America, JPMorgan, UBS and Truist raising price targets; the stock now has a Moderate Buy consensus and an average target price of $41.78.
• Teva insiders have also been selling shares recently, including two EVP transactions, and insiders sold a total of 421,470 shares worth about $14.6 million over the past 90 days.

BNP Paribas Financial Markets trimmed its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 10.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 561,231 shares of the company's stock after selling 64,277 shares during the quarter. BNP Paribas Financial Markets' holdings in Teva Pharmaceutical Industries were worth $17,516,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Global Retirement Partners LLC increased its holdings in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock valued at $42,000 after acquiring an additional 292 shares during the period. Banque Cantonale Vaudoise increased its stake in Teva Pharmaceutical Industries by 6.3% in the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company's stock valued at $160,000 after buying an additional 306 shares during the period. Ethic Inc. increased its stake in Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Ethic Inc. now owns 18,127 shares of the company's stock valued at $566,000 after buying an additional 325 shares during the period. Allworth Financial LP increased its stake in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock valued at $29,000 after buying an additional 329 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock valued at $32,000 after buying an additional 345 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Thursday, April 30th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, April 30th. Truist Financial boosted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, April 30th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $41.78.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $35.61, for a total value of $5,457,268.11. Following the sale, the executive vice president directly owned 172,184 shares of the company's stock, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares in the company, valued at approximately $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 421,470 shares of company stock worth $14,570,945 in the last 90 days. Insiders own 0.54% of the company's stock.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported new real-world survey data showing AUSTEDO and AUSTEDO XR improved quality-of-life measures for Huntington’s disease chorea patients and reduced caregiver strain, supporting the outlook for one of its key branded medicines. Article Title
• Positive Sentiment: Teva expanded its European biosimilars business with the launch of AHZANTIVE, strengthening its growth strategy and broadening its presence in ophthalmology. Article Title
• Neutral Sentiment: Industry coverage highlighted Teva as a generic-drug stock to watch as biosimilars, complex generics and specialty drugs become increasingly important growth drivers. Article Title

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $34.21 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The stock has a market cap of $39.34 billion, a PE ratio of 25.72, a price-to-earnings-growth ratio of 3.49 and a beta of 0.84. The firm's fifty day simple moving average is $32.82 and its 200-day simple moving average is $31.63.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion for the quarter. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.